Reduced proliferation and increased apoptosis of the SGC‑7901 gastric cancer cell line on exposure to GDC‑0449

Wu,Chuanqing; Cheng,Ji; Hu,Shaobo; Deng,Rui; Muangu,Yamba Willy; Shi,Liang; Wu,Ke; Zhang,Peng; Chang,Weilong; Wang,Guobin; Tao,Kaixiong

doi:10.3892/mmr.2015.4677

Reduced proliferation and increased apoptosis of the SGC‑7901 gastric cancer cell line on exposure to GDC‑0449

Authors:
- Chuanqing Wu
- Ji Cheng
- Shaobo Hu
- Rui Deng
- Yamba Willy Muangu
- Liang Shi
- Ke Wu
- Peng Zhang
- Weilong Chang
- Guobin Wang
- Kaixiong Tao
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: December 11, 2015 https://doi.org/10.3892/mmr.2015.4677
Pages: 1434-1440

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The sonic hedgehog (Shh) pathway is known to be vital in embryonic development and cancer propagation due to its irreplaceable role in cell proliferation and differentiation. GDC‑0449, a basal cell skin cancer target drug approved by the Food and Drugs Administration, is a smoothened (Smo)‑specific antagonist. Although it has been clinically verified as a valid drug for the treatment of skin and pancreatic cancer, the application of GDC‑0449 in gastric cancer requires further investigation. In the present study, high‑glucose Dulbecco's modified Eagle's medium with 10% fetal bovine serum was used for routine SGC‑7901 cell line culture. A Cell Counting Kit‑8 assay was employed for determination of the reproductive rate of the cells. Flow cytometry was performed to determine the apoptosis status of the SGC‑7901 cell line through Q4 analysis. Reverse transcription‑quantitative polymerase chain reaction and Western blot analyses were used as target molecule detection vehicles. As expected, GDC‑0449 reduced the expression levels of Shh‑associated molecules, including Smo and gli1, compared with the blank group. The rate of cell proliferation was markedly limited and was accompanied by an increase in the apoptotic rate following GDC‑0449 exposure. In addition, further investigations confirmed B cell lmyphoma‑2 (Bcl‑2) as the downstream molecular mechanism of GDC‑0449 efficacy. Of note, representatives of the cancer stem cell (CSC) surface marker, CD44 and CD133, demonstrated a similar trend to the Smo restriction observed. By repressing the expression of Bcl‑2, GDC‑0449 inhibited the normal proliferation of SGC‑7901 cells, and accelerated the apoptotic rate of the cells. It may also alter CSC properties due to the reduction in the expression of surface markers.

View Figures

View References

1	Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS and Rabkin CS: Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 303:1723–1728. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhang WH, Chen XZ, Liu K, Chen XL, Yang K, Zhang B, Chen ZX, Chen JP, Zhou ZG and Hu JK: Outcomes of surgical treatment for gastric cancer patients: 11-year experience of a Chinese high-volume hospital. Med Oncol. 31:1502014. View Article : Google Scholar : PubMed/NCBI
4	Kwon IG, Cho I, Choi YY, Hyung WJ, Kim CB and Noh SH: Risk factors for complications during surgical treatment of remnant gastric cancer. Gastric Cancer. 18:390–396. 2015. View Article : Google Scholar
5	Vorechovský I, Benediktsson KP and Toftgård R: The patched/hedgehog/smoothened signalling pathway in human breast cancer: No evidence for H133Y SHH, PTCH and SMO mutations. Eur J Cancer. 35:711–713. 1999. View Article : Google Scholar : PubMed/NCBI
6	Romer J and Curran T: Targeting medulloblastoma: Small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res. 65:4975–4978. 2005. View Article : Google Scholar : PubMed/NCBI
7	Athar M, Li C, Kim AL, Spiegelman VS and Bickers DR: Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res. 74:4967–4975. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wang Y, Wang Y, Dong J, Wei W, Song B, Min H, Yu Y, Lei X, Zhao M, Teng W and Chen J: Developmental hypothyroxinemia and hypothyroidism reduce proliferation of cerebellar granule neuron precursors in rat offspring by downregulation of the sonic hedgehog signaling pathway. Mol Neurobiol. 49:1143–1152. 2014. View Article : Google Scholar
9	Petrova E, Rios-Esteves J, Ouerfelli O, Glickman JF and Resh MD: Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling. Nat Chem Biol. 9:247–249. 2013. View Article : Google Scholar : PubMed/NCBI
10	Álvarez-Buylla A and Ihrie RA: Sonic hedgehog signaling in the postnatal brain. Semin Cell Dev Biol. 33:105–111. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chen M, Qian Y, Dai J and Chu R: The sonic hedgehog signaling pathway induces myopic development by activating matrix metalloproteinase (MMP)-2 in Guinea pigs. PLoS One. 9:e969522014. View Article : Google Scholar : PubMed/NCBI
12	Schaefer GI, Perez JR, Duvall JR, Stanton BZ, Shamji AF and Schreiber SL: Discovery of small-molecule modulators of the Sonic Hedgehog pathway. J Am Chem Soc. 135:9675–9680. 2013. View Article : Google Scholar : PubMed/NCBI
13	Stanton BZ and Peng LF: Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst. 6:44–54. 2010. View Article : Google Scholar
14	Woodland HR: Some studies on early embryonic development relevant to the study of cancer. J Clin Pathol Suppl (R Coll Pathol). 7:26–30. 1974. View Article : Google Scholar
15	Martin GR: Teratocarcinomas as a model system for the study of embryogenesis and neoplasia. Cell. 5:229–243. 1975. View Article : Google Scholar : PubMed/NCBI
16	Omenetti A and Diehl AM: The adventures of sonic hedgehog in development and repair II. Sonic hedgehog and liver development, inflammation and cancer. Am J Physiol Gastrointest Liver Physiol. 294:G595–G598. 2008. View Article : Google Scholar : PubMed/NCBI
17	Batsaikhan BE, Yoshikawa K, Kurita N, Iwata T, Takasu C, Kashihara H and Shimada M: Cyclopamine decreased the expression of sonic hedgehog and its downstream genes in colon cancer stem cells. Anticancer Res. 34:6339–6344. 2014.PubMed/NCBI
18	Li X, Wang Z, Ma Q, Xu Q, Liu H, Duan W, Lei J, Ma J, Wang X, Lv S, et al: Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Clin Cancer Res. 20:4326–4338. 2014. View Article : Google Scholar : PubMed/NCBI
19	Chen JS, Huang XH, Wang Q, Huang JQ, Zhang LJ, Chen XL, Lei J and Cheng ZX: Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis. 34:10–19. 2013. View Article : Google Scholar
20	Rosow DE, Liss AS, Strobel O, Fritz S, Bausch D, Valsangkar NP, Alsina J, Kulemann B, Park JK, Yamaguchi J, et al: Sonic Hedgehog in pancreatic cancer: From bench to bedside, then back to the bench. Surgery. 152(3 Suppl 1): S19–S32. 2012. View Article : Google Scholar : PubMed/NCBI
21	Rodova M, Fu J, Watkins DN, Srivastava RK and Shankar S: Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS One. 7:e460832012. View Article : Google Scholar : PubMed/NCBI
22	Jeng KS, Sheen IS, Jeng WJ, Yu MC, Hsiau HI, Chang FY and Tsai HH: Activation of the sonic hedgehog signaling pathway occurs in the CD133 positive cells of mouse liver cancer Hepa 1–6 cells. Onco Targets Ther. 6:1047–1055. 2013. View Article : Google Scholar
23	Che L, Yuan YH, Jia J and Ren J: Activation of sonic hedgehog signaling pathway is an independent potential prognosis predictor in human hepatocellular carcinoma patients. Chin J Cancer Res. 24:323–331. 2012. View Article : Google Scholar
24	Amin SH, Tibes R, Kim JE and Hybarger CP: Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope. 120:2456–2459. 2010. View Article : Google Scholar : PubMed/NCBI
25	Singh BN, Fu J, Srivastava RK and Shankar S: Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS One. 6:e273062011. View Article : Google Scholar : PubMed/NCBI
26	Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ and Efstathiou E: Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 72:1638–1647. 2012. View Article : Google Scholar : PubMed/NCBI
27	Li QQ, Skinner J and Bennett JE: Evaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment. BMC Mol Biol. 13:222012. View Article : Google Scholar : PubMed/NCBI
28	Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 12:17–20. 2006.PubMed/NCBI
29	Papenfuss WA, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U and Wilkinson NW: Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 21:3008–3014. 2014. View Article : Google Scholar : PubMed/NCBI
30	De Luca A, Parmigiani E, Tosatto G, Martire S, Hoshino M, Buffo A, Leto K and Rossi F: Exogenous Sonic hedgehog modulates the pool of GABAergic interneurons during cerebellar development. Cerebellum. 14:72–85. 2015. View Article : Google Scholar
31	Lewis S: Neural development: Double agent sonic hedgehog. Nat Rev Neurosci. 14:666–667. 2013. View Article : Google Scholar : PubMed/NCBI
32	Courchet J and Polleux F: Sonic hedgehog, BOC and synaptic development: New players for an old game. Neuron. 73:1055–1058. 2012. View Article : Google Scholar : PubMed/NCBI
33	Xu X, Ding H, Rao G, Arora S, Saclarides CP, Esparaz J, Gattuso P, Solorzano CC and Prinz RA: Activation of the Sonic Hedgehog pathway in thyroid neoplasms and its potential role in tumor cell proliferation. Endocr Relat Cancer. 19:167–179. 2012. View Article : Google Scholar : PubMed/NCBI
34	Shaw A, Gipp J and Bushman W: The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts. Oncogene. 28:4480–4490. 2009. View Article : Google Scholar : PubMed/NCBI
35	Lin J, Wei L, Shen A, Cai Q, Xu W, Li H, Zhan Y, Hong Z and Peng J: Hedyotis diffusa Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer angiogenesis. Int J Oncol. 42:651–656. 2013. View Article : Google Scholar : PubMed/NCBI
36	Dahmane N, Lee J, Robins P, Heller P and Ruiz i Altaba A: Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature. 389:876–881. 1997. View Article : Google Scholar
37	Fan H, Oro AE, Scott MP and Khavari PA: Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med. 3:788–792. 1997. View Article : Google Scholar : PubMed/NCBI
38	Dreno B, Basset-Seguin N, Caro I, Yue H and Schadendorf D: Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. 19:790–796. 2014. View Article : Google Scholar : PubMed/NCBI
39	Yin VT, Sniegowski M and Esmaeli B: Indications and limitations of vismodegib for basal cell carcinoma. JAMA Ophthalmol. 132:905–906. 2014. View Article : Google Scholar : PubMed/NCBI
40	Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, et al: Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (Vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 20:5937–5945. 2014. View Article : Google Scholar : PubMed/NCBI
41	Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, et al: Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 17:5774–5782. 2011. View Article : Google Scholar : PubMed/NCBI
42	Tang SN, Fu J, Nall D, Rodova M, Shankar S and Srivastava RK: Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer. 131:30–40. 2012. View Article : Google Scholar :
43	Heiden KB, Williamson AJ, Doscas ME, Ye J, Wang Y, Liu D, Xing M, Prinz RA and Xu X: The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression. J Clin Endocrinol Metab. 99:E2178–E2187. 2014. View Article : Google Scholar : PubMed/NCBI